Updated: May 12, 2023
NYS DOH implemented the transition all at once, effective April 1, 2023.
Updated: July 8, 2022
Yes, NYS DOH anticipates an increase in both federal and state supplemental rebates due to the transition to a single standardized formulary, which will allow the State to optimize federal rebates and increase the State's leverage to negotiate supplemental rebates with manufacturers.
Updated: July 8, 2022
NYS DOH believes the transition of the pharmacy benefit from Managed Care (MC) to the Medicaid NYRx Pharmacy program is in the best interest of the Medicaid program and Medicaid beneficiaries, and that it will achieve the objectives outlined in FAQ 001 . As such, NYS DOH is confident that the pharmacy transition will generate savings.
Updated: July 8, 2022
Yes, DOH has consulted for and with several other states, including California and Michigan, regarding their transition of the pharmacy benefit from Managed Care to Fee-For-Service. In addition, DOH participated on a multi-state working group to discuss implementation strategies related to the pharmacy benefit transition and garnered insight from various states specific to the transition. These conversations and activities have informed and continue to guide DOH's approach in implementation of the transition.
Updated: May 12, 2023
Communication about the transition of the pharmacy benefit to NYRx has been done by both NYS DOH and the MCPs and has been accomplished through a variety of methods including letters and Medicaid Update articles. Additional information regarding these communications and their timing can be found within the Transition and Communications Activities Timeline document.
Updated: July 8, 2022
No, NYS DOH does not intend to engage in exclusive contracts with particular specialty pharmacy providers, as part of the pharmacy benefit transition.
Updated: July 8, 2022
NY State participates in the National Medicaid Pooling Initiative (NMPI) to access supplemental rebates for drugs included in the Preferred Drug Program.
Questions regarding the NMPI bid solicitation may be sent to: NYPDPnotices@magellanhealth.com.
Questions regarding the Preferred Diabetic Supply Program may be submitted via the contact form.
Questions regarding any other products subject to the carve-out may be sent to: NYPDPnotices@magellanhealth.com.
Updated: June 20, 2023
The New York State´s Medicaid Section 1115 MRT Waiver (formerly known as the Partnership Plan) is the current authority under which the pharmacy benefit is delivered by the Managed Care Plans (MCPs). Since the pharmacy benefit has transitioned to the Medicaid NYRx Pharmacy program, the 1115 MRT Waiver must be amended accordingly to support the transition.
Updated: June 20, 2023
Having transitioned to the Medicaid NYRx Pharmacy program on April 1, 2023, Hemophilia Treatment Centers will bill the NYRx program for covered drugs and products that are included in the outpatient pharmacy program. This includes outpatient prescription drugs and clotting factor. More detail regarding the drugs and other products that are included in the outpatient pharmacy benefit can be found at the following link.
Updated: June 20, 2023
There is currently no separate 340B formulary. Essentially, the 340B Covered Entity determines whether they will use 340B drugs for Medicaid members. Effective April 1, 2023, the pharmacy benefit has transitioned to NYRX, in which MC members will access their pharmacy benefit through the NYRx program and providers submitting 340B claims for MC members, will follow Medicaid NYRx Pharmacy program billing policies for 340B claims.
Updated: June 20, 2023
No, there have not been any changes in the way in which 340B claims will be submitted now that the pharmacy benefit has transitioned from Managed Care (MC) to NYRx. If there are changes, they will be communicated to providers via a Medicaid Update article. For information on how to bill 340B claims please see the 2021 November Medicaid Update.
Updated: July 8, 2022
The Pharmacy Benefit Transition from Managed Care (MC) to the Medicaid NYRx Pharmacy program will have no impact to providers ability to use the 340B program for Medicare or dually eligible beneficiaries. Information regarding the Health Resources and Services Administration (HRSA) requirements for Covered Entities can be found by accessing the following link.
Information regarding Medicaid FFS 340B claim submission requirements, including submission requirements for dually eligible members can be found at the following link.
Updated: July 8, 2022
Presentation copies for 340B Advisory Group meetings are posted on the NYS DOH MRT II NY Medicaid Pharmacy Program (NYRx) website under the "Stakeholder Engagement" section and are organized by date.
Published: July 8, 2022
Yes, NYS DOH has reviewed and considered several alternative 340B models, including the Texas Shared Savings model. After careful consideration of these models, NYS DOH believes that the pharmacy transition, including the reinvestment of 340B savings to Covered Entities, achieves the policy goals that are in the best interest of the Medicaid program and its beneficiaries. These policy goals are outlined in slide # 4 of the August 17th, 2020 All Stakeholder meeting.
Updated: July 8, 2022
No, the Pharmacy Benefit Transition will not result in moving contracted pharmacies out of clinics. Such decisions are left to 340B Covered Entities. If a clinic makes the decision to move their contracted pharmacies out of their clinics, patients will continue to have access to needed medications at another Medicaid enrolled pharmacy. If a Covered Entity does choose to move their contracted pharmacy out of their clinics, NYS DOH would not anticipate any negative impacts to Medicaid members accessing their medications.
Published: December 14, 2022
The Pharmacy Benefit Transition does not require 340B entities to carve in pharmacy/clinic/physician administered Medicaid claims at either the Covered Entity or its contract pharmacies.
Updated: June 20, 2023
The Medicaid NYRx Pharmacy Benefit Transition does not apply to Managed Long-Term Care plans (e.g., PACE, MAP, Partial MLTC, MLTC), the Essential Plan, or Child Health Plus (CHP).
The NYRx Medicaid Pharmacy Benefit Transition applies to all mainstream Managed Care Plans (MCPs), including Health and Recovery (HARP) and HIV-Special Needs (SNP) plans. More information can be found on slide 3 of the Transition of the Pharmacy Benefit from Managed Care to Fee-for-Service (FFS): Implementation Update & Strategy presentation.
Published: August 4, 2020
MCPs will continue to be responsible for maintaining all activities necessary for their enrolled members' care coordination and claims payment for non-outpatient pharmacy services and related activities, consistent with contractual obligations. The MCPs will determine the personnel and resources that they need in order to continue to perform these functions.
Information regarding MCPs and NYS DOH roles can be found at the following link. NYS DOH will work closely with the MCPs to provide access to pharmacy data that is necessary to support the activities for which they are responsible.
Published: November 8, 2022
The pharmacy benefit transition only applies to the Medicaid pharmacy benefit. Managed Care Plans (MCPs) will continue to be responsible for providing other benefits, such as medical benefits, etc.
Updated: July 8, 2022
NYS DOH and its actuary will adjust MC rates to account for the pharmacy benefit being transitioned to the Fee-For-Service (FFS) program. Per federal regulations, all Medicaid MC rates are required to be actuarially sound.
Updated: July 8, 2022
NYS DOH discussed the topic of VBP arrangements with MCPs and subject matter experts during multiple Technical Workgroup meetings. MCPs were asked to review the data file format along with other data sharing and prior authorization information and consider whether these provide the data and information needed to support VBP arrangements.
Based on this evaluation, NYS DOH does not view the transition of the Pharmacy Benefit to Medicaid Fee-for-Service (FFS) as a barrier for existing or future VBP arrangements. NYS DOH will be delivering data to the plans in the form of a daily claims file (please refer to FAQ 056 and FAQ 104), as well as a set of on-demand reports (please refer to the to the Transition and Communication Activities Timeline). These reports will provide for timely access to critical data and ensure that existing VBP arrangements between MCPs and providers continue post transition.
Updated: July 8, 2022
NYS DOH discussed the topic of HEDIS/QARR measures with MCPs and subject matter experts during multiple Technical Workgroup meetings. MCPs were asked to review the data file format along with other data sharing and prior authorization information and consider whether these provide the data and information needed to support reporting HEDIS/QARR.
It was determined that the current QARR measures were largely in place prior to the 2011 Carve-In - current measures can be found in the eQARR online report. More than 50% of total QARR measures use pharmacy data in the measurement calculation (e.g., denominator, numerator, or both) - pharmacy data will continue to be important. It is NYS DOH's assumption that all quality measures will continue to be calculated and reported by health plans as a part of QARR reporting. It is also NYS DOH's assumption that plans will need pharmacy data in order to report out on QARR measures. The data sharing between NYS DOH and MCPs will support continued reporting on measures.
Lastly, NYS DOH provided responses to the MCPs to support plans in answering Table 1.4 Ancillary Provider Data in Section 1: Medical Services and Processing of the HEDIS Roadmap. For more information regarding QARR reporting please refer to FAQ 070.
Updated: May 14, 2021
The Transition and Communication Activities Timeline has been developed and reviewed collaboratively with the Managed Care Plans at recurring Technical Workgroup meetings.
Updated: July 8, 2022
The pharmacy benefit transition will not impact the critical risk groups (CRGs) methodology or process. The current risk adjustment methodology utilizes both Managed Care (MC) encounters and Fee-For-Service (FFS) claims as grouper inputs.
FAQ 048 How will the upcoming changes affect medical benefit drugs? Will Managed Care Plans (MCP) set policy for the utilization of medical benefit drugs, or will NYS DOH establish a utilization management policy for the MCPs to follow? Will Managed Care Plans (MCPs) utilize their own formulary or the Medicaid NYRx Pharmacy formulary for practitioner-administered drugs that are currently billed to MCPs?
Updated: July 8, 2022
The transition will not change the MCPs' responsibility for developing coverage and billing policies for practitioner administered drugs for their members, as referenced in the Scope of Benefits document. MCPs will continue to make practitioner administered drugs available when billed as a medical or institutional claim.
Updated: July 8, 2022
NYS DOH and the Office of the Medicaid Inspector General (OMIG) will work with the MCPs to develop and implement modified procedures that support the Restricted Recipient Program.
Updated: July 8, 2022
The pharmacy data file that will be sent from NYS DOH would be considered administrative data for use of QARR reporting. NCQA will consider it as encounter data for the purposes of reporting. Please note that the data file is currently undergoing design through collaboration with the Managed Care Plans (MCPs).
Updated: July 8, 2022
The MCP should inquire with the NCQA health plan auditor requesting that information.
Updated: July 8, 2022
DME supplies found within the Durable Medical Equipment, Prosthetics, Orthotics, Supplies and Procedure Codes and Coverage Guidelines will remain the responsibility of the MCPs and therefore should not be impacted for discontinuation of a Prior Authorization (PA) or rental with respect to the pharmacy benefit transition. More guidance will be forthcoming regarding DME supplies found within the Pharmacy Procedures & Supply Codes as review and analysis is in progress.
Updated: July 8, 2022
Syringes and needles are subject to the Pharmacy Benefit Transition and therefore will be covered under the Medicaid NYRx Pharmacy Program. More information regarding needles and syringe products can be found on page 17 within Section 4.2 Enteral And Parenteral Therapy of the Pharmacy Procedures & Supply Codes manual.
Updated: May 12, 2023
Medicaid Managed Care Plans (MCPs) must continue to comply with federal and State requirements to monitor and report all cases of potential fraud, waste, and abuse. The MCP administers the medical benefits and, as of 4/1/23, the MCP will receive the pharmacy daily claims file to allow for a complete medical claim review. If an MCP suspects fraud, waste, or abuse, they should report that to the Office of the Medicaid Inspector General (OMIG).
Additional information can be found on the Office of the Medicaid Inspector General's Medicaid Managed Care Fraud, Waste, and Abuse Prevention Programs Guidance and Forms page.
In addition, MCPs are required to provide comprehensive care management and care coordination. This includes but is not limited to evaluation of medication adherence, medical appointments, initial filling of medications for targeted disease states, etc.
As of 4/1/23, the MCPs began receiving a daily claims file of pharmacy claims to allow for a completion of the above activities.
Updated: June 20, 2023
As the pharmacy benefit is transitioned to the NYRx program effective April 1, 2023, the Medicaid Pharmacy List of Reimbursable Drugs will continue to be used and updated as it is today. The full list of reimbursable drugs may be viewed online or downloaded. Likewise, the Medicaid NYRx Pharmacy reimbursement methodology will be used.
Published: October 12, 2022
There will not be any changes to the coverage criteria for MAT therapy with this transition and MAT therapy will continue to be covered by NYRx for all Medicaid enrollees. Prior authorization is not required for medications used for the treatment of substance use disorder when prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder.
Updated: July 8, 2022
The transition will not change the way in which the DUR Board operates. Information regarding the DUR Board can be found at the following link.
Published: November 5, 2020
NYS DOH has a standard process that is utilized for the Medicaid NYRx Pharmacy Program to collect bids from manufacturers under the Preferred Drug Program (PDP) as well as the Preferred Diabetic Supply Program (PDSP). It is the intent of NYS DOH to continue to utilize that process consistent with how it has been handled in NYRx.
As referenced in the October 19 th , 2020 All Stakeholder Presentation, NYS DOH analyzed managed care claims by program area to inform transition strategy. Slides 12 &13 of this presentation provide details regarding this analysis and the transition strategy that will be used to ensure continued access to medications.
Published: July 26, 2023
The Drug Utilization Review Board (DURB) provides recommendations for preferred drugs based on FDA labeling and current clinical practice guidelines. Trial of one preferred drug, within a recent timeframe, is usually sufficient unless otherwise indicated on the PDL.
Published: July 26, 2023
If a Medicaid member has experienced a loss or theft of medication, pharmacy providers should instruct members to contact their prescriber. The decision to honor a member’s request for authorization of a replacement supply is based on the professional judgement of the prescriber. Prescribers may initiate a prior authorization request for a lost or stolen medication by contacting the eMedNY Call Center at 800-343-9000. Replacement, if granted, will be approved for up to a 30-day supply of medication.
Please refer to NYRx Pharmacy Policy Manual for information on lost or stolen medication.
Published: July 26, 2023
Generally, drugs are limited to the FDA approved dosing, and most maintenance drugs have a 90-day supply limit.
Published: July 26, 2023
NYRx updates prescription claim editing based on current drug shortage information. For example, to assist with patient needs, NYRx may remove PA criteria for a drug or drug class based on shortages and/or leverage additional NDCs that may be available in the marketplace.
Published: July 26, 2023
A pharmacist should consult the prescriber for any requested changes to a prescription. Please refer to Article 137 of NYS Education Law for more information.
Published: July 26, 2023
One of the Drug Utilization Review Board (DURB) responsibilities is to review therapeutic classes subject to the preferred drug program (PDP). The DURB may also need to review the drug or drug class before clinical criteria may be applied. Drugs will be evaluated on a case-by-case basis to determine if they are appropriate to add to the pharmacy formulary. More information on the DUR review and PDL lists/requirements can be found in the Pharmacy Provider Manual.
Updated: May 14, 2021
Yes. Information regarding future stakeholder meetings will be sent out via the MRT LISTSERV.
Updated: July 8, 2022
Presentation copies for All Stakeholder meetings are posted on the NYS DOH MRT II NY Medicaid Pharmacy Program (NYRx) website under the "Stakeholder Engagement" section and are organized by date.
Updated: July 8, 2022
The All Stakeholder meetings have been established to update stakeholders and to gather input from all stakeholders, including individuals and families, and those that represent them.
Updated: July 8, 2022
The Technical Workgroup meetings began on July 21, 2020 and will be held bi-weekly thereafter. The meetings are not to the public.
Updated: September 4, 2020
The Technical Workgroup is composed of Pharmacy Directors of each Managed Care Plan (MCP). NYS DOH will lead targeted discussions regarding specific topics and issues that require clarification and resolution in order to move the transition forward. MCPs will assist with the development of discussion documents and recommendations.
Updated: July 8, 2022
Outputs from Technical Workgroups will be posted on the NYS DOH MRT II NY Medicaid Pharmacy Program (NYRx) website once finalized.
Updated: July 8, 2022
Stakeholders who are not members of the 340B Advisory Group or Technical Workgroup can participate in the Pharmacy Benefit Transition by attending the All Stakeholders meetings. The All Stakeholders meetings began on July 13, 2020 and occur the third Monday of each month. Stakeholders should subscribe to the MRT LISTSERV to receive announcements and registration links for the meetings (typically sent out 1 week in advance of the meeting). Additionally, the MRT LISTSERV is a valuable resource for staying up to date and informed about website updates and resource postings.
Published: November 5, 2020
If you are experiencing issues with receiving MRT LISTSERV messages or subscribing, please contact mrtupdates@health.ny.gov for assistance. The MRT Team will be able to verify your subscription or manually subscribe you.
Updated: December 14, 2022
The transition will include covered outpatient drugs and other products covered under the Medicaid Pharmacy Program. This includes outpatient prescription and over-the-counter drugs, diabetic, incontinence and other supplies. It does not include physician administered (J-Code) drugs. More information regarding what drugs and products are included in the NYRx Medicaid Pharmacy Program can be found within the Medicaid List of Reimbursable Drugs (Formulary File) and the List of OTC Categories and Supply Codes .
Updated: October 12, 2022
The Scope of Benefits document will be updated and clarified based on stakeholder comments or questions. Information regarding specific outpatient drugs covered by the NYRx Medicaid Pharmacy program, and whether a prior authorization is required can be found on the eMedNY website.
When the pharmacy benefit transitions to NYRx, many Managed Care (MC) members will be able to continue taking their medication, without needing prior authorization. NYS DOH will leverage clinical editing criteria which may allow for members to continue to receive non-formulary/non-preferred medication. Additionally, prior authorizations established in Managed Care will continue to be honored and could allow for non-formulary/non-preferred drug coverage. Furthermore, there will be a transition period from April 1, 2023 through June 30, 2023. During this period, members will be provided with a one-time, temporary fill for drugs that would normally require prior authorization under the NYRx Preferred Drug Program (PDP). This allows additional time for prescribers to either seek prior authorization or change to a preferred drug, which does not require prior authorization. Refer to FAQ 113 for information on the Transition Period.
Published: September 4, 2020
Outpatient Antibiotics and maintenance medications will be covered by the NYRx Medicaid Pharmacy program, when billed by a pharmacy. Information regarding specific outpatient drugs covered under the NYRx program can be found on the eMedNY website.
Published: September 4, 2020
Long Acting 2nd generation antipsychotics, when administered by a physician or other practitioner in a clinic setting and billed on an institutional or medical claim form will continue to be covered by the member's managed care plan.
The NYRx Pharmacy Program covers drugs that are indicated for FDA approved/compendia supported uses. Compendia support does include off-label uses that have proven efficacy. The official specific references currently identified can be found in the Social Security Act Section 1927(g)(1)(B)(i).
See FAQ 054b above.
Updated: July 8, 2022
Only pharmacy supply and procedure codes are subject to the pharmacy benefit transition unless otherwise stated within the Pharmacy Scope of Benefits. Pharmacy billing guidance and a list of supply codes for pharmacies and DME suppliers can be found on the eMedNY Pharmacy website. DME billing guidance is available as a PDF.
Updated: July 8, 2022
Mastectomy care is subject to the pharmacy benefit transition and will therefore be covered under the Medicaid Fee-For-Service (FFS) program. Breast and hair prosthesis will be the responsibility of the Managed Care Plans (MCPs). For more information, please review the Pharmacy Supply and Procedure Manual and the Pharmacy Scope of Benefits.
Updated: July 8, 2022
Vivitrol is subject to the transition and will be covered under the Medicaid NYRx pharmacy benefit. Managed Care Plans (MCPs) will continue to be responsible to cover Vivitrol for their members when it is billed as a medical or institutional claim.
Updated: July 8, 2022
External ambulatory infusion pumps for insulin are not part of the pharmacy benefit transition and will remain the responsibility of the Managed Care Plans (MCPs). More information can be found within Appendix A of the Pharmacy Scope of Benefits.
Updated: July 8, 2022
Durable Medical Equipment, Prosthetics, Orthotics, and Supplies not found within in the Pharmacy Procedures and Supplies Manual are not subject to the transition and will remain the responsibility of the Managed Care Plans (MCPs). For more information, refer to Appendix A of the Pharmacy Scope of Benefits.
Updated: July 8, 2022
Preferred CGM devices should be billed via the Medicaid NYRx Pharmacy Benefit and are subject to the Preferred Diabetic Supply Program (PDSP) list. Information regarding pharmacy billing guidance and a list of supply codes for pharmacies and DME suppliers can be found on the eMedNY Pharmacy website.
Non-Preferred CGM devices should be billed under the medical benefit. Information regarding DME billing guidance is available as a PDF.
Updated: July 8, 2022
NYS DOH is evaluating MCP pharmacy claim encounters to determine potential differences in coverage for medications. The New York State Medicaid Pharmacy program, NYRx, covers medically necessary FDA approved prescription and select non-prescription drugs for Medicaid NYRx members based on program rules. NYS DOH is evaluating MCP pharmacy claim encounters to determine potential differences in coverage areas for medications.
Oncology medications that are typically administered by practitioners may not be on the Medicaid NYRx formulary as they are not considered part of the pharmacy benefit. However, they are still a covered Medicaid benefit. MCPs will continue to make practitioner administered oncology medications available when they are billed as a medical or institutional claim.
Updated: June 20, 2023
Yes, the Pharmacy Procedures & Supply Codes manual contains products that were subject to the transition, which will be able to be billed as either a pharmacy claim via NCPDP or billed as a medical claim through Fee-For-Service (FFS). Effective April 1, 2023, these supplies are no longer to be billed to the Managed Care Plan (MCP).
Updated: June 20, 2023
Prior Authorizations that were issued by Medicaid Managed Care (MMC) plans prior to April 1, 2023 (that are active/valid after April 1, 2023) have been honored by the Medicaid Pharmacy program, NYRx. This includes clinical PAs that also require authorization under the Medicaid NYRx Pharmacy program.
Published: November 8, 2022
The existing process which requires the Drug Utilization Review Board (DURB) to review new drugs and drug classes for inclusion in the PDP will continue, and new therapeutic classes may be added in the future.
Published: November 8, 2022
No. The Elderly Pharmaceutical Insurance Coverage (EPIC) program is separate from the NYS Medicaid Program. and will not be affected by the transition.
Published: December 14, 2022
If the program criteria is met then the non-preferred drugs may not require prior authorization.
Published: December 14, 2022
Under NYRx, members have access to a very comprehensive list of drugs/drug classes. All members will be subject to the same coverage and utilization management protocols. If there is a drug or drug class that is not on the formulary, a medical necessity request can be submitted for review.
Published: January 12, 2023
NYRx does not require additional enrollment requirements or accreditations to dispense specialty drugs. Pharmacies enrolled in Medicaid Fee-For-Service (FFS) may dispense and bill for covered outpatient drugs.
Published: January 12, 2023
NYRx, the Medicaid Pharmacy program publishes a full listing of drugs and clinical criteria for the Preferred Drug Program, Clinical Drug Review Program (CDRP), DUR Program, Brand Less than Generic Program (BLTG), Dose Optimization Program and the Mandatory Generic Drug Program (MGDP)on the Magellan Medicaid Administration Website.
Updated: June 20, 2023
The existing Fee-For-Service billing processes for these services is continuing to be utilized following the transition to NYRx on April 1, 2023. See pages 5 through 8 of the Medicaid Pharmacy Procedure Codes for a list of services and supplies that have or have not been affected by the transition.
Published: February 17, 2023
The HCPCS codes "G2082" and "G2083" should not be billed to the NYS Medicaid program. These codes are a bundled payment and are not eligible for rebate collection per federal rule and, therefore, are not listed as covered by the program. These codes are only authorized for use on Medicare crossover claims. Spravato may be billed as pharmacy or medical benefit per the guidance below.
See the March 2022 Medicaid Update Article titled Pharmacy and Medical Billing Guidance for SPRAVATO® (esketamine) and the August 2022 MU Article titled Practitioner Administered Drug Update: New York State Medicaid Fee-for-Service Policy Guidance for SPRAVATO® (Esketamine) Nasal Spray for additional information.
Published: February 17, 2023
Physician administered drugs not included on the List of Reimbursable drugs will be reimbursed using the medical benefit irrespective of location of administration. Please see the Provider Manual for NYRx members and refer to the Managed Care Plan for their processes for Managed Care enrollees. More information can also be found in FAQ 031 and FAQ 048.
The Department continues to evaluate the potential additions of more physician administered drugs on the pharmacy outpatient formulary. For the most updated information, please refer to the NYRx Formulary File.
Published: March 17, 2023
Enteral and parenteral nutrition, family planning and medical/surgical supplies found in the Pharmacy Procedures and Supply Codes are subject to the transition and can be billed to NYRx as a pharmacy or medical claim.
Infusion pumps for enteral or parenteral nutrition found in the Sections 4.4, 4.5, 4.6, and 4.7 of the Durable Medical Equipment, Prosthetics and Supplies Manual are not subject to the transition and remain the responsibility of the MC plans.
Published: July 26, 2023
NYRx does not cover certain diagnoses and certain drugs or drug classes due to federal regulations. At this time, NYRx does not cover medications, such as Wegovy or Ozempic, when indicated for the treatment of weight loss.
For more information regarding excluded drugs under the Medicaid benefit, please see the April 2022 Medicaid Update.
Published: July 26, 2023
Please refer to the NYRx preferred drug list (PDL) for details about coverage criteria for drugs covered by NYRx with utilization management. Additionally, Providers can view the Medicaid Pharmacy List of Reimbursable Drugs for a complete listing of drugs, including biologics covered by the NYRx pharmacy benefit. Physician administered drugs, including biologics, continue to be covered by the Managed Care Plans (MCPs).
Published: July 26, 2023
Children, under 21 years of age, enrolled in Medicaid are exempt from copayments. Pharmacies must accept reimbursement as payment in full. It is inappropriate for a NYS Medicaid provider to request or charge additional fees to a member.
Published: July 26, 2023
Medical providers can continue to submit medication claims using the medical benefit. Please see the Provider Manual for NYRx members and refer to the Managed Care Plan for their processes for Managed Care enrollees. Medications found on the List of Reimbursable Drugs are also covered as a pharmacy benefit.
Published: July 26, 2023
Breast pumps, other than hospital grade pumps, are included in the transition, please refer to the Scope of Benefits document. There is no change to prescribing providers.
Please refer to the DME manual for information on pages 9-12. For more information regarding DME supplies reach out to ohipmedpa@health.ny.gov.
Published: July 26, 2023A prior approval request must be submitted for any amount over the allowed quantities. This approval should include documentation supporting the medical necessity of the request amounts. This request can be submitted via paper PA or ePACES with uploaded documentation. For specific procedural guidance, please refer to the March 2023 Medicaid Update, the DME policy guidelines on the eMEdNY site or contact DME by email at ohipmedpa@health.ny.gov for information on billing of DME supplies.
Updated: November 8, 2022
Existing Medicaid members will not receive a new NYS Benefit Card, also known as the Common Benefit Identification Card (CBIC), and there will be no change to member ID numbers. Members can show either their existing NYS Benefit Card or their Managed Care Health Plan Card at the pharmacy.
Published: November 5, 2020
There will not be designated specialty pharmacies within the Medicaid NYRx Pharmacy Program nor are there any presently. Members will be able to access any NYRx pharmacy for drugs that are on the outpatient NYRx formulary. NYS DOH is reviewing the physician administered drugs and may add some of those drugs to the outpatient NYRx formulary.
Lastly, NYS DOH is working closely with the Managed Care Plans to ensure that they (MCPs) will be able to provide members continued access to those drugs.
Updated: July 8, 2022
After April 1, 2023, members and providers with questions or complaints associated with DME/supplies subject to the transition, should contact 800-342-3005 or ohipmedpa@health.ny.gov.
Updated: July 8, 2022
Starting on April 1, 2023, Medicaid Managed Care (MMC) members should present either their MMC plan or Medicaid Identification Card to their pharmacist and remind him/her about the transition to Medicaid NYRx. Both cards contain the Client Identification Number (CIN), which the pharmacist uses to submit their claims to the Medicaid NYRx program.
For most members, there will be no change at the pharmacy counter.
Members should review the letter notifying them of the change, to be sure that their pharmacy takes the Medicaid Pharmacy Program, NYRx (most pharmacies do), and that their drugs are covered. Refer to FAQ 051 and FAQ 098 for information regarding the transition period and prior authorizations previously granted by MMC plans. The PowerPoint presentation (slides 4-6), from the December 22, 2020 All Stakeholder Meeting also provides information regarding what members can expect.
Updated: July 8, 2022
Patients can verify if their current pharmacy is enrolled by accessing the eMedNY website for members. The resource is accessible here. Select the tool for "Find a Pharmacy/Medical Equipment Supplier."
Updated: June 20, 2023
NYS DOH has existing processes in place to allow for the approval of emergency medication supply when a member receives services from an out-of-state non-enrolled provider, which is continuing to be leveraged now that the Transition has occurred.
Published: November 8, 2022
No. Patients still have the option to receive their oral prescriptions directly from their physician. Medical billing will not be impacted by the pharmacy benefit transition. The transition will not change the Managed Care Plan responsibility for developing coverage and billing policies for prescription drugs that are billed on medical and institutional claims.
NYSDOH Fee-For-Service has expanded medical billing [New York State Medicaid Update. (2022, July). Policy Clarification for Practitioner Dispensing] so that practitioners can use the existing medical claims format to be reimbursed for drugs furnished to Medicaid Fee-For-Service patients. This expands access so that all practitioners serving Medicaid Managed Care and Fee-For-Service patients can use the same claims format. The use of existing medical billing does not change how Medicaid patients can obtain their prescriptions, and use of this existing billing procedure does not add extra steps or complex barriers preventing patients from receiving treatment. Allowing all Medicaid physicians to bill for medications furnished to their patients, using the established billing procedure ensures patient care coordination and drug availability at the point of service.
Published: December 14, 2022
Most major chains and independent pharmacies located in New York are enrolled in the Medicaid program. Data regarding the number of pharmacies enrolled in the Medicaid program may be found on the Medicaid Enrolled Provider Listing.
Published: December 14, 2022
Yes, members can use one of the 5,700+nparticipating pharmacy or DME supplier enrolled in NYRx.
Published: December 14, 2022
A member will need to use an NYRx enrolled provider. If a member's current pharmacy does not take NYRx, a member should ask their pharmacist to transfer a refill to a participating pharmacy or ask their doctor to send their prescriptions to a participating pharmacy.
Published : February 17, 2023NYS Medicaid ensures an ample supply of medication(s) to accommodate for most temporary absences and allows a 90-day supply for most maintenance medications.
For more information, refer to the August 2021 Medicaid Update article titled, Clarification and Reminder: Pharmacy Providers Servicing Medicaid Fee-for-Service Members.
Updated: March 17, 2023Members notices of change were sent to members in February. Please refer to Member Notice of Change Mailing Tracker for a schedule of the mailings. Additionally, please visit the NYRx Information for Medicaid Members website for member information.
Members also can contact their Managed Care Plan (MCP) for the letter translated in their preferred language.
Updated: June 20, 2023
Delivery of prescription drugs, over-the-counter products, medical/surgical supplies, and medical equipment (DME) is an optional service that can be provided to Medicaid member's home or current residence including facilities and shelters. Pharmacies/DME providers must obtain a signature from the Medicaid member, their caregiver or their designee to confirm receipt of the prescription drugs, over-the-counter products, medical/surgical supplies, or DME items. Claim submission is not proof that the prescription or fiscal order was actually furnished.
For more information on delivery, please refer to page 12 of the Pharmacy Provider Manual.
Published: March 17, 2023
Members must utilize a NYS Medicaid FFS enrolled pharmacy. Drugs covered by NYRx subject to limit distribution will be available from Medicaid enrolled limited distribution pharmacies. If these limited distribution pharmacies are not located in NYS they will not show up in the look up tool. The pharmacy should be contacted to confirm they are enrolled in NYRx for this benefit. Providers can also check enrollment through the Medicaid Enrolled Provider List.
Updated: June 20, 2023
Limited Distribution drugs remain available following the Pharmacy Benefit Transition on April 1, 2023. NYRx has pharmacies enrolled that dispense limited distribution drugs, most of which are currently servicing Managed Care enrollees. Managed Care Plans are responsible for transitioning members to enrolled pharmacies if the pharmacy they are utilizing is not enrolled in NYRx. Members were noticed if they needed to choose another pharmacy and may reach out to their Managed Care Plans for questions for their specific needs.
Published: March 17, 2023
A prescription or fiscal order is required for non-prescription OTCs. There are some exceptions, and a fiscal order or prescription is not required for OTC emergency contraception for Medicaid-eligible females, and Covid-19 test kits.
Prescribers and pharmacies have received extensive information regarding the Pharmacy Benefit transition to ensure a positive experience for NY Medicaid members.
Updated: June 20, 2023
Fair hearings are a process administered by the Office of Temporary and Disability Assistance (OTDA), which is operational today and has continued to be utilized following the Transition. However, by leveraging NYRx's Prior Authorization request process, most of these issues can be addressed without utilizing the fair hearing process.
Published: March 17, 2023
Members may continue to receive their prescriptions from their mail order pharmacy as long as the pharmacy is enrolled in the NYRx program. To verify enrollment please visit the Search for a Pharmacy or Medical Equipment Supplier tool.
Updated: June 20, 2023
There are no changes in the copay requirements, including the provider's responsibility to provide services when the member is unable to pay a copay. For information, please see the Pharmacy Manual (pages 45-46).
Published: May 12, 2023
If primary insurance coverage is no longer active or has changed, a member would need to contact either their Local District, NY State of Health or HRA NYC, depending on where they had their Medicaid eligibility determined, to update their Medicaid application. Please contact the Human Resource Administration (HRA) for New York City at (718) 557-1399 or the Medicaid Helpline (800) 541-2831. For Local District contact information please visit: New York State Local Departments of Social Services (LDSS) (ny.gov)
Published: July 26, 2023
Managed Care Plans were not required to issue a new health plan ID card specific to the pharmacy benefit transition. Members may present their existing health plan ID card or the NYS Benefit Card, also known as the Common Benefit Identification Card (CBIC) card at the pharmacy.
Published: July 26, 2023
Yes, NYRx does allow prescription transfers. New York State Education Law Article 137 Section 6810 (10-a) Title 8, New York Codes, Rules and Regulations Section 63.6 (a)(8), provisions are to be followed for prescription transfers. For Medicaid specific information regarding transfers please see the NYRx policy manual .
Updated: June 20, 2023
As the pharmacy benefit has transitioned into the NYRx Medicaid Pharmacy program on April 1, 2023, children in foster care that are already enrolled in Managed Care Plans (MCPs) have begun to receive their outpatient pharmacy benefit through the NYRx program.
Foster care children that transition from FFS into a Managed Care Plan (MCP) for their medical benefit will continue to receive their pharmacy benefit through the NYRx program.
Published: October 12, 2022
Foster Care parents should contact the Voluntary Foster Care Agencies (VCFA) for assistance with obtaining necessary billing information. Foster Care parents can also show the Managed Care Health Plan Card which contains the Client Identification Number (CIN) the pharmacist uses to submit their claims to the Medicaid NYRx
Published: August 4, 2020
Providers that are prescribing outpatient drugs (or other products covered under the outpatient pharmacy benefit),for Managed Care (MC) members, will access the NYRx formulary and the Preferred Drug List to determine coverage parameters. Pharmacies that are billing for outpatient drugs for MC members will submit claims to the eMedNY system.
Updated: July 8, 2022
Covered generic medications will be paid in accordance with the Medicaid Pharmacy NYRx Pharmacy Reimbursement methodology.
Updated: July 8, 2022
Information regarding pharmacy reimbursement can be found within the Medicaid Pharmacy NYRx Pharmacy Reimbursement methodology.
Updated: July 8, 2022
Pharmacies (mail order and non-mail order) that are currently serving Medicaid Managed Care members, but are not enrolled in the Medicaid FFS program, may submit their applications to the FFS program. The Department of Health will consider the number of Medicaid managed care members and claims currently being handled by pharmacy applicants.
Information for submitting applications can be found on page 10 within the October 2020 Medicaid Update Article entitled Attention: Pharmacies, Durable Medical Equipment, Prosthetics, Orthotics and Supply Providers, and Prescribers That are Not Enrolled in Medicaid Fee-for-Service.
Updated: July 8, 2022
Delivery directly to a member's home is allowed under the Guidelines for the Delivery of Medical/Surgical Supplies and Durable Medical Equipment (pg.19) within the Durable Medical Equipment Manual Policy Guidelines. The guidelines specify the types of supplies that may be delivered, documentation required to be retained by the billing provider, and requirements and responsibility of the billing provider for lost or misdirected shipments.
Revised Guidelines will be available with the next Manual Update.
Updated: July 8, 2022
MLTC Plans are not impacted by the Pharmacy Benefit Transition. See FAQ 017.
Published: November 8, 2022
Yes, for more information please refer to the Scope of Benefits, Chart #2.
Updated: July 8, 2022
Starting April 1, 2023, pharmacies will submit claims to the Medicaid Fee-For-Service (FFS) program, using the Client Identification Number (CIN), which can be found on the member's Medicaid or the MMC plan Identification Card. Additional information regarding claim submission can be found within the December 2020 Special Edition Medicaid Update.
Updated: November 8, 2022
Pharmacies and practitioners must be enrolled in NYS Medicaid Fee-For-Service (FFS), to service Medicaid members. For exceptions, refer to FAQ 112. Information on how to enroll in NYS Medicaid (FFS) can be found here.
Published: November 8, 2022
Additional enrollment is not required for pharmacies that are currently enrolled in NYS Medicaid FFS. NYRx is the new name for the pharmacy benefit under the New York State Medicaid Program. Nothing has changed with the Medicaid pharmacy program except the name. Pharmacies must maintain enrollment with NYS Medicaid FFS to continue to service Medicaid members.
Published: November 8, 2022
No additional enrollment action is needed from practitioners who are enrolled with NYS Medicaid as an ordering, prescribing, referring, and attending (OPRA) provider.
Practitioners enrolled with Medicaid as an OPRA provider are considered to be enrolled in NYS Medicaid Fee-For-Service (FFS) as a qualified non-billing provider. More information on how to check a provider's enrollment status can be found with in the June 2022 Medicaid Update Article: Reminder: Medicaid Enrollment Requirements and Compliance Deadlines for Managed Care Providers.
Providers who wish to enroll as non-billing OPRA provider may do so on the eMedNY "Provider Enrollment and Maintenance" web page.
Published: October 12, 2022
Individual providers should be enrolling in Medicaid Fee-For-Service (FFS). Practice sites may facilitate enrollment for providers; however, providers must sign the NYS Medicaid FFS contract agreement individually. For more information, please visit the eMedNY Practitioner Group Enrollment page.
Published: October 12, 2022
There are existing processes in place to process claims from non-enrolled providers. Circumstances in which the override process may be used, include medical emergencies or for services provided by an intern, resident, or foreign physician who cannot enroll in the NYS Medicaid Program. Please see the April 2022 Medicaid Update for more information.
Published: November 8, 2022
No. To be eligible for reimbursement by the Medicaid program, the practitioner that issues the standing order must be enrolled in Medicaid Fee-For-Service (NYRx) and the non-enrolled prescriber override should not be utilized in this scenario.
Published: October 12, 2022
Prior to the transition period, NYS DOH will be outreaching high volume prescribers of non-formulary/non-preferred products to educate them on the NYRx preferred drug program and clinical criteria. Additionally, during the transition period, from April 1, 2023, to June 30, 2023 (90 days), NYS DOH will be conducting outreach to prescribers to inform them of the members receiving non-preferred products in order to familiarize with Preferred Drug Program. For more information on the transition fill, refer to FAQ 051.
Published: November 8, 2022
During the transition period from April 1, 2023 through June 30, 2023, members will be provided with a one-time, temporary fill for up to a 30 day supply of a drug that would normally require prior authorization under the NYRx Preferred Drug Program (PDP). This allows additional time for prescribers to either seek prior authorization or change to a preferred drug, which does not require prior authorization. Refer to FAQ 051 and FAQ 113.
Updated: June 20, 2023
Practitioners who dispense prescription drugs to Medicaid patients submit claims through medical billing. Medical billing is not impacted by the pharmacy benefit transition. The transition did not change the Managed Care Plan responsibility for developing coverage and billing policies for prescription drugs that are billed on medical and institutional claims.
Published: November 8, 2022
Yes, NYRx has access to historical prescription claims and clinical editing has the capability to look back at all claims submitted from the Medicaid Managed Care Plans.
Published: December 14, 2022
When a provider contacts the call center, they will speak with a pharmacy technician. The technician will collect relevant information and ask the appropriate criteria questions. If the technician can approve the prior authorization based on the provider's responses, a prior authorization will be created. If the call needs to be escalated because the technician cannot approve, it may go to the pharmacist for a more in-depth clinical conversation. If further discussion is warranted, a peer-to-peer consultation may be utilized if necessary.
Published: December 14, 2022
Pharmacies can check a member's Medicaid eligibility status through any of the following methods:
Method | Summary |
---|---|
E1 Transaction | Instructions for E1 transactions begin on page 10 of the NCPDP D.0 Standard Companion Guide |
ePACES | Providers must have an ePACES account and the member's CIN to check their eligibility status. |
Published: January 12, 2023
No. The same copay exemptions still apply. NYRx does not track point of service waived copays. More information on copayments including exemptions, payment collection and billing can be found in the Pharmacy Provider Manual (pages 41 & 42).
Published: January 12, 2023No. The pharmacy must be enrolled in the NYS Medicaid program, and enrolled pharmacies are eligible for reimbursement of covered vaccination services.
Published: January 12, 2023
Yes, members and providers will receive letters regarding non-preferred products recently utilized by the member. A one-time transition fill will be provided before prior authorization is required. For more information on the transition fill period please reference FAQ 051, FAQ 113, and FAQ 124.
Published: January 12, 2023
Providers will need to obtain a new prior authorization for oral enteral products. Please refer to the DME Provider Manual for more information (page 35).
Published : February 17, 2023
Providers should direct billing and payment questions to the eMedNY Call Center at (800) 343-9000. For more information for pharmacy providers, please refer to the Pharmacy Quick Reference guide. Additional billing information can be found in the January 2023 Medicaid Update Special Addition Part Two.
Published : February 17, 2023
No. Pharmacists can dispense brand name drugs subject to the BLTG program without prescriber intervention. For information on the BLTG program, please refer here.
Published : February 17, 2023
The NYRx Pharmacy Provider Manual has guidance for override situations, including lost or stolen prescriptions (page 8) and obtaining Prior Authorization for 72-hour emergency supply (page 13). Please visit the Provider Manual for guidance on unlicensed residents, interns, and foreign physician in training programs (page 24), and Out-of-State (OOS) Licensed Prescribers (page 25).
For override guidiance on early fills pertaining to vacation or a temporary absence, please refer to the August 2021 Medicaid Update. For override guidiance on early fills pertaining to lost or stolen medication, please refer to the Provider Manual (page 8).
Published: March 17, 2023
All Medicaid Managed Care (MMC) network furnishing, ordering, prescribing, referring and attending (OPRA) providers must be enrolled with New York State (NYS) Medicaid FFS, including telemedicine providers. Effective September 1, 2022, MMC Plans began to deny payment to unenrolled pharmacies, other unenrolled practitioners, and providers for services provided and/or prescribed. Providers servicing MMC members should, without delay, begin the enrollment process and complete all required forms, including certifications. Please refer to the April 2022 Medicaid Update article titled Medicaid Enrollment Requirements and Compliance Deadlines for Managed Care Providers.
Published: March 17, 2023
NYS Medicaid does not require a prescription to filled within 60 days of the date written. Effective June 24, 2021, prescriptions are valid and may be filled for up to one year from the date issued. After the prescription expires, new prescriptions will be required from prescribers, even when refills remain on the original prescriptions. Refill and PA allowance may be less based on the Federal Drug Administration (FDA) labeling and/or best practices.
Published: March 17, 2023
The List of Medicaid Reimbursable Drugs has been established by the New York State Commissioner of Health. Only those prescription and non-prescription drugs which appear on the List are reimbursable under NYRx . The List also contains those nonprescription therapeutic categories which the Commissioner of Health has specified as essential in meeting the medical needs of Medicaid members. The entire List is available electronically.
There is a Search tool for OTC and Prescription Drugs Tool is designed for members to provide general information regarding drugs covered under the NYRx program.
Published: May 12, 2023
The Magellan clinical call center will utilize the NPI to verifying the identity of the presciber or their agent.
Published: May 12, 2023
The Magellan Education and Outreach (E&O) call center cannot discuss specific member concerns until they can verify a caller using NPI or a designated users IVN. The IVN is a number assigned by Magellan for Medicaid Managed Care Plans (MCPs) only. The process to become a designated user is an internal process between the Department, Managed Care Plans, and Magellan.
Published: May 12, 2023
Yes, in emergency situations providers can contact the eMedNY call center at 1-800-343-9000. However, providers should direct members to their place of Medicaid enrollment to update their eligibility and request removal of any inactive coverage from their records. Please contact the Human Resource Administration (HRA) for New York City at (718) 557-1399 or the Medicaid Helpline (800) 541-2831. For Local District contact information please visit: New York State Local Departments of Social Services (LDSS) (ny.gov).
Published: May 12, 2023
The Restricted Recipient Program (RRP) is an Office of the Medicaid Inspector General (OMIG) program. Providers and members can reach out to their Managed Care Plan (MCP) to find out who their restricted providers are. Additionally, members can contact their Local District to determine who their restricted providers are. For Local District contact information please visit: New York State Local Departments of Social Services (LDSS) (ny.gov). The upcoming Medicaid Update will include more information regarding the RRP and billing guidelines for restricted recipients.
Published: June 20, 2023
Medicaid covers a limited benefit for dual eligible beneficiaries including select prescription vitamins, cough formulations and OTC products. There are no changes in the copay requirements, including the provider's responsibility to provide services when the member is unable to pay a copay. For information, please see the Pharmacy Manual (pages 44-46).
Published: June 20, 2023
The MMC Plan Identification (ID) number card contains the Client Identification Number (CIN), which is unique to NYS Medicaid members and MMC enrollees and should be used to bill NYRx. The CIN is always represented in the following form at "XX00000X", and in some cases, the CIN may be embedded in the MMC Plan ID Number of the enrollee. The CIN can be found on both the Plan ID Card and NYS Medicaid CBIC of the NYS Medicaid member and MMC enrollee.
A chart containing the CIN format for each MMC Plan ID card can be found in the New York State Medicaid Update - January 2023 Volume 39 - Number 2 (ny.gov). Card samples which identify the CIN location on the MMC Plan ID card can be found on the New York State Medicaid Managed Care (MMC) Pharmacy Benefit Information Center website.
For more information regarding member eligibility checks refer to FAQ 134.
Published: July 26, 2023
Yes, residents, interns, and foreign physicians can prescribe utilizing override codes under NYRx. Billing information and guidance for prescriptions written by residents, interns, and foreign physicians can be found in the May 2023 Special Edition Medicaid Update.
Physician Assistants, as well as Nurse Practitioners (NP), are required to enroll in the NYS Medicaid FFS program as either a billing provider or OPRA provider to prescribe to Medicaid members.
Published: July 26, 2023
Please contact the NYS Medicaid DME team by email at ohipmedpa@health.ny.gov For assistance with specific questions on criteria or for claims processing and resources please contact eMedNY.
Published: July 26, 2023
Yes, member and providers were notified prior to the transition that they or their patients were on a non-preferred drug. This notice encouraged providers to review the NYRx Preferred Drug List to become familiar with the NYRx pharmacy program and preferred drug list.
Updated: June 20, 2023
As the pharmacy benefit has transitioned to the Medicaid NYRx Pharmacy program on April 1, 2023, NYS DOH will use the eMedNY system for point-of-sale claims adjudication. This is the claims adjudication system which is currently used for Medicaid members that access all their benefits through the FFS program.
Updated: June 20, 2023
Providers can still leverage the CoverMyMeds platform via the PA fax process with Magellan. Surescripts is not be available following April 1, 2023.
Published: September 4, 2020
NYS DOH will collaborate with the Office of the Medicaid Inspector General (OMIG) to develop processes to evaluate and address potential duplicate claims for drugs that are available through the pharmacy and medical benefit.
Updated: July 8, 2022
The 5-limit refill rule on medications is no longer in place. Effective, May 1, 2021, prescriptions are valid and may be filled for up to one year from the date issued. Once the prescription expires, a new prescription from the prescriber would be required.
Contraceptives continue to be available for a one-year supply, per the November 2019 Medicaid Update Article, providing that the prescriber writes the prescription for a one-year supply.
Updated: July 8, 2022
Medical supply companies enrolled in Medicaid Fee-For-Service (FFS) as a Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) provider can bill pharmacy supplies and procedures subject to the pharmacy benefit transition.
Updated: July 8, 2022
Yes. There is a plan in place for NYS DOH systems and call centers to have the capacity to manage the increased volume of claims and inquiries regarding DME/Supplies subject to the transition.
Published: October 12, 2022
NYS DOH will be utilizing existing call centers, in which processes are already in place that serve the current diverse population of NYS Medicaid members. Call centers are familiar with the needs of Medicaid members, have the skills and training to prevent disruption, and NYS DOH have prepared trainings in anticipation of new call center staff being added.
Published: December 14, 2022
No, the transition fill will be automatically adjudicated via the eMedNY claims processing system. There will be an approved response message sent alerting the pharmacy that the claim paid as a transition fill.
Updated: June 20, 2023
The claims processing call center has weekend hours currently. The Department has evaluated those hours and made adjustments as necessary. The Magellan clinical call center is available 24/7. Program staff have monitored real-time claims over the course of the implementation.
Published: February 17, 2023
The eMedNY claims processing system will populate NCPDP field 548-6F, Approved Message Code, with code "005" – Claim paid under the plan's transition benefit period, otherwise claim would have rejected as PA is required. Please refer to the January 2023 Medicaid Update Special Addition Part Two for more information.
Published: February 17, 2023
Claim capture is available. Transaction instructions are available on eMedNY.
Published: July 26, 2023
The Brand Less Than Generic (BLTG) Program is a cost containment initiative which promotes the use of certain multi-source brand name drugs when the cost of the brand name drug is less expensive than the generic equivalent. This program conforms with State Education Law, which intends that a patient receive the lower cost alternative. State Education Law does not specify DAW code values.
Published: July 26, 2023
Pharmacy claims can be reversed real-time. For real-time pharmacy transaction instructions please refer to the NCPDP Companion Guide. Providers must ensure that the claim is an ECCA claim and information regarding ECCA claims can be found here. Providers can also contact eMedNY for assistance.
Updated: June 20, 2023
NYS DOH has provided a data claims file to the Managed Care Plans (MCP) beginning April 1, 2023. Through the Technical Workgroup, NYS DOH has collaborated with MCPs to obtain consensus on the data file that has been created.
Updated: June 20, 2023
The NYS DOH supplies a claims file to the Managed Care Plans (MCPs). Through the Technical Workgroup, NYS DOH has collaborated with MCPs to obtain consensus on the data file and data elements (e.g. member information) that are needed.
Updated: June 20, 2023
NYS DOH has continued working with Managed Care Plans (MCPs) to ensure claims utilization data will be provided to the Medicaid MCPs daily, for the previous day's activity. Daily pharmacy utilization data sharing was previously tested and reviewed and tested in anticipation of the Pharmacy Benefit Transition implementation date, and MCPs have been receiving daily claims data beginning April 1, 2023.
Published: July 26, 2023
Care management continues to be the responsibility of the Managed Care Plans (MCPs). NYRx provides the MCPs daily claim information for clinical management and care coordination, as well as weekly medication adherence and first fill reports. The MCPs remain responsible for medical claims, including hospital claims. More information regarding MCPs roles and responsibilities can be found in the Pharmacy Benefit Transition roles and responsibilities document.